Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck
George Fountzilas, Aristotelis Bamias, Anna Kalogera-Fountzila, Georgia Karayannopoulou, Mattheos Bobos, Eleni Athanassiou, Konstantine T Kalogeras, Christos Tolis, Periklis Tsekeris, Pavlos Papakostas, Chrysanthi Vamvouka, Thomas Zaramboukas, Paris Kosmidis, Nikolaos Zamboglou, Despina Misailidou, George Fountzilas, Aristotelis Bamias, Anna Kalogera-Fountzila, Georgia Karayannopoulou, Mattheos Bobos, Eleni Athanassiou, Konstantine T Kalogeras, Christos Tolis, Periklis Tsekeris, Pavlos Papakostas, Chrysanthi Vamvouka, Thomas Zaramboukas, Paris Kosmidis, Nikolaos Zamboglou, Despina Misailidou
Abstract
Background: Induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) has the potential of being an ideal multi-modality approach for improving the prognosis of patients with squamous cell carcinoma of the head and neck (SSCHN).
Patients and methods: Thirty-four patients with locally advanced SCCHN were treated with 3 cycles of IC, consisting of docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks, followed 3-4 weeks later by definitive radiotherapy (70 Gy) and concomitant weekly cisplatin 40 mg/m2.
Results: After a median follow-up of 27.7 months, 6-month progression-free survival (PFS), the primary study end-point, was 84%. The median PFS was 16.4 months and median overall survival 24.4 months. The majority of the patients completed 3 cycles to moderate toxicity. Anemia, nausea/vomiting and mucositis were the prominent toxicities during CCRT. Retrospective analysis of a panel of biomarkers suggested that excision repair cross-complementation group 1 (ERCC1) protein expression was associated with shorter PFS.
Conclusion: IC followed by CCRT, as administered in the present study, is a feasible and well-tolerated therapeutic approach. However, its real impact on the prognosis of SCCHN patients has to be demonstrated in a randomized study comparing this treatment to CCRT alone.
Source: PubMed